Sio Gene Therapies Debt 2024

Sio Gene Therapies Aktienanalyse

What does Sio Gene Therapies do?

Sio Gene Therapies Inc. is a biopharmaceutical company focused on developing gene therapies for rare genetic diseases. The company was founded in 2000 by a team of scientists specializing in the research of gene therapies for the treatment of rare diseases. Sio Gene Therapies' history began with the goal of providing an alternative treatment method for patients with rare diseases. The company focuses on the discovery and development of gene therapies based on the use of vectors to deliver genes into defective cells. The company has focused on diseases such as Huntington's chorea, Parkinson's disease, and rare hereditary diseases. Sio Gene Therapies' business model is designed to develop and market gene therapy as a novel therapy for rare diseases. The company pursues an innovative research program that aims to discover rare diseases and identify genetic mutations associated with these diseases. Sio Gene Therapies collaborates with leading scientists and research institutions to develop innovative approaches to the treatment of rare genetic diseases. Sio Gene Therapies has several divisions, including a research facility, a development department, and a sales department. Each of these departments plays a crucial role in the development of gene therapies for rare diseases. The research department identifies new target genes for the development of gene therapies, the development department develops and tests vectors for gene therapy, and the sales department works closely with physicians and health authorities to market and make gene therapy available. Sio Gene Therapies has developed a range of products based on gene therapy. This includes Axovant, a gene therapy for the treatment of Parkinson's disease that aims to deliver genes into defective cells. The drug is currently in the clinical testing stage. Peroxysome biogenesis disorder (PBD) is a rare hereditary disease caused by a dysfunction of peroxisomes. The company has already completed initial clinical studies with its product AXO-AAV-CLN6, a gene therapy approach for PBD. The results of these studies are promising, and the company is currently in Phase III of clinical studies. Sio Gene Therapies has achieved several milestones in recent years. In 2017, the company received approval from the U.S. Food and Drug Administration (FDA) for its first gene therapy for the treatment of rare degenerative retinal diseases. In August 2020, the company initiated a Phase III study for the treatment of PBD with AXO-AAV-CLN6. Overall, Sio Gene Therapies has established itself as a successful company in the gene therapy industry and has specialized in the development of gene therapies for rare genetic diseases. The company has made significant progress in the development of gene therapies in recent years and has also received important approvals from the FDA. Through ongoing research and development of new products, the company intends to contribute to the treatment and cure of rare genetic diseases in the future. Sio Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Sio Gene Therapies's Debt Structure

Sio Gene Therapies's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Sio Gene Therapies's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Sio Gene Therapies’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Sio Gene Therapies’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Sio Gene Therapies Stock

What is the debt of Sio Gene Therapies this year?

Sio Gene Therapies has a debt level of -63.7 USD this year.

What was the debt of Sio Gene Therapies compared to the previous year?

The debt of Sio Gene Therapies has increased by -46.47% compared to the previous year dropped.

What are the consequences of high debt for investors in Sio Gene Therapies?

High debt can pose a risk for investors of Sio Gene Therapies, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Sio Gene Therapies?

Low debt means that Sio Gene Therapies has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Sio Gene Therapies affect the company?

An increase in debt of Sio Gene Therapies can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Sio Gene Therapies affect the company?

A reduction in debt of Sio Gene Therapies can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Sio Gene Therapies?

Some factors that can influence the debt of Sio Gene Therapies include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Sio Gene Therapies so important for investors?

The debts of Sio Gene Therapies are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Sio Gene Therapies take to change the debt?

To change the debt, Sio Gene Therapies can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Sio Gene Therapies pay?

Over the past 12 months, Sio Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sio Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Sio Gene Therapies?

The current dividend yield of Sio Gene Therapies is .

When does Sio Gene Therapies pay dividends?

Sio Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sio Gene Therapies?

Sio Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Sio Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sio Gene Therapies located?

Sio Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sio Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sio Gene Therapies from 6/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Sio Gene Therapies pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Sio Gene Therapies in the year 2023?

In the year 2023, Sio Gene Therapies distributed 0 USD as dividends.

In which currency does Sio Gene Therapies pay out the dividend?

The dividends of Sio Gene Therapies are distributed in USD.